The Asia Pacific Diabetes Care Devices Market would witness market growth of 6.1% CAGR during the forecast period (2022-2028).
Diabetes technology refers to the gear, gadgets, and software that diabetic people use to help them manage their blood glucose levels, avoid diabetes complications, lessen the burden of diabetes, and improve their quality of life. Traditionally, diabetes care technology has been separated into two categories viz. insulin delivered via pen, syringe, or pump, and blood glucose monitoring via meter or continuous glucose monitor. More recently, diabetes technology has developed to include hybrid devices that monitor glucose and dispense insulin, sometimes automatically, as well as software that acts as a medical device and helps people manage their diabetes. When used effectively, diabetes technology can enhance people's lives and health.
Insulin pens are more convenient since they combine the vial and the syringe into one device. Insulin pens with preloaded cartridges or reusable insulin pens with changeable insulin cartridges are available for push-button injections. Some reusable pens have a remembering capability that allows the user to recall dosing amounts and times. There are also smartpens that can be configured to compute insulin doses and generate downloadable data reports. Pens also differ in terms of dosing increments and minimum doses, which can range from half-unit to two-unit increments.
There is high adoption of an unhealthy and sedentary lifestyle in this region. According to the International Diabetes Federation, 90 million adults (20-79) in the IDF South-East Asia region will have diabetes. By 2030, this number is expected to rise to 113 million, and by 2045, to 152 million. Undiagnosed diabetes affects 46 million people in the IDF SEA Region, accounting for 51% of all adults with diabetes in the region. Impaired Glucose Tolerance (IGT) affects 47 million people in the IDF SEA Region, putting them at risk of developing type 2 diabetes. By 2030, this number is estimated to rise to 59 million, with 77 million by 2045. In the IDF SEA Region, diabetes was accountable for 747,000 fatalities in 2021.
In China, unhealthy diets and a lack of physical activity are contributing to rising rates of obesity and overweight, both of which are risk factors for Type 2 diabetes. In China, more than a third of adults are overweight, with 7% of them being obese. Children in China are also in danger of acquiring diabetes due to unhealthy lifestyles as more than 4 in 5 adolescents aged 11 to 17 do not get enough physical activity, as well as rates of obesity and overweight in children, are rapidly rising. As a result, increased diabetes incidence would propel the growth of the diabetes care devices market.
The China market dominated the Asia Pacific Diabetes Care Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2,232.9 Million by 2028. The Japan market is estimated to grow at a CAGR of 5.5% during (2022 - 2028). Additionally, The India market would witness a CAGR of 6.8% during (2022 - 2028).
Based on Product, the market is segmented into Insulin Delivery Devices and Blood Glucose Monitoring Devices. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Diabetes Care Devices Market is Projected to reach USD 29.3 Billion by 2028, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., DexCom, Inc., Novo Nordisk A/S, Sanofi S.A., Zealand Pharma A/S, B. Braun Melsungen AG, Bayer AG, Abbott Laboratories, Ypsomed AG, Arkray, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Insulin Delivery Devices and
- Blood Glucose Monitoring Devices
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- F. Hoffmann-La Roche Ltd.
- DexCom, Inc.
- Novo Nordisk A/S
- Sanofi S.A.
- Zealand Pharma A/S
- B. Braun Melsungen AG
- Bayer AG
- Abbott Laboratories
- Ypsomed AG
- Arkray, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Diabetes Care Devices Market, by Product
1.4.2 Asia Pacific Diabetes Care Devices Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements : 2018, Oct – 2022, May) Leading Players
Chapter 4. Asia Pacific Diabetes Care Devices Market by Product
4.1 Asia Pacific Insulin Delivery Devices Market by Country
4.2 Asia Pacific Blood Glucose Monitoring Devices Market by Country
Chapter 5. Asia Pacific Diabetes Care Devices Market by Country
5.1 China Diabetes Care Devices Market
5.1.1 China Diabetes Care Devices Market by Product
5.2 Japan Diabetes Care Devices Market
5.2.1 Japan Diabetes Care Devices Market by Product
5.3 India Diabetes Care Devices Market
5.3.1 India Diabetes Care Devices Market by Product
5.4 South Korea Diabetes Care Devices Market
5.4.1 South Korea Diabetes Care Devices Market by Product
5.5 Singapore Diabetes Care Devices Market
5.5.1 Singapore Diabetes Care Devices Market by Product
5.6 Malaysia Diabetes Care Devices Market
5.6.1 Malaysia Diabetes Care Devices Market by Product
5.7 Rest of Asia Pacific Diabetes Care Devices Market
5.7.1 Rest of Asia Pacific Diabetes Care Devices Market by Product
Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Product Launches and Product Expansions:
6.2 DexCom, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expenses
6.2.5 Recent strategies and developments:
6.2.5.1 Partnerships, Collaborations, and Agreements:
6.2.5.2 Product Launches and Product Expansions:
6.2.5.3 Acquisition and Mergers:
6.3 Novo Nordisk A/S
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental & Regional Analysis
6.3.4 Research & Development Expenses
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.3.5.2 Acquisition and Mergers:
6.4 Sanofi S.A.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.4.5.2 Product Launches and Product Expansions:
6.5 Zealand Pharma A/S (Valeritas, Inc.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Research & Development Expenses
6.5.4 Recent strategies and developments:
6.5.4.1 Product Launches and Product Expansions:
6.5.4.2 Approvals and Trials:
6.6 B. Braun Melsungen AG
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expenses
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Bayer AG
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expense
6.7.5 Recent strategies and developments:
6.7.5.1 Partnerships, Collaborations, and Agreements:
6.7.5.2 Approvals:
6.8 Abbott Laboratories
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.8.5.2 Approvals:
6.9 Ypsomed AG
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Recent strategies and developments:
6.9.4.1 Partnerships, Collaborations, and Agreements:
6.10. Arkray, Inc.
6.10.1 Company Overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Geographical Expansions:
TABLE 1 Asia Pacific Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 2 Asia Pacific Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Diabetes Care Devices Market
TABLE 4 Product Launches And Product Expansions– Diabetes Care Devices Market
TABLE 5 Acquisition and Mergers– Diabetes Care Devices Market
TABLE 6 Geographical expansion– Diabetes Care Devices Market
TABLE 7 Approvals and Trials– Diabetes Care Devices Market
TABLE 8 Asia Pacific Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 9 Asia Pacific Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 10 Asia Pacific Insulin Delivery Devices Market by Country, 2018 - 2021, USD Million
TABLE 11 Asia Pacific Insulin Delivery Devices Market by Country, 2022 - 2028, USD Million
TABLE 12 Asia Pacific Blood Glucose Monitoring Devices Market by Country, 2018 - 2021, USD Million
TABLE 13 Asia Pacific Blood Glucose Monitoring Devices Market by Country, 2022 - 2028, USD Million
TABLE 14 Asia Pacific Diabetes Care Devices Market by Country, 2018 - 2021, USD Million
TABLE 15 Asia Pacific Diabetes Care Devices Market by Country, 2022 - 2028, USD Million
TABLE 16 China Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 17 China Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 18 China Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 19 China Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 20 Japan Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 21 Japan Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 22 Japan Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 23 Japan Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 24 India Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 25 India Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 26 India Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 27 India Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 28 South Korea Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 29 South Korea Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 30 South Korea Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 31 South Korea Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 32 Singapore Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 33 Singapore Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 34 Singapore Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 35 Singapore Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 36 Malaysia Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 37 Malaysia Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 38 Malaysia Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 39 Malaysia Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 40 Rest of Asia Pacific Diabetes Care Devices Market, 2018 - 2021, USD Million
TABLE 41 Rest of Asia Pacific Diabetes Care Devices Market, 2022 - 2028, USD Million
TABLE 42 Rest of Asia Pacific Diabetes Care Devices Market by Product, 2018 - 2021, USD Million
TABLE 43 Rest of Asia Pacific Diabetes Care Devices Market by Product, 2022 - 2028, USD Million
TABLE 44 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 45 Key Information – DexCom, Inc.
TABLE 46 Key information – Novo Nordisk A/S
TABLE 47 Key Information – Sanofi S.A.
TABLE 48 Key Information – Zealand Pharma A/S
TABLE 49 key Information – B. Braun Melsungen AG
TABLE 50 Key Information – Bayer AG
TABLE 51 Key Information – Abbott Laboratories
TABLE 52 Key Information –-Ypsomed AG
TABLE 53 Key Information – Arkray, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, collaborations and agreements : 2018, oct – 2022, may) Leading Players
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 6 Recent strategies and developments: DexCom, Inc.
FIG 7 Recent strategies and developments: Novo Nordisk A/S
FIG 8 Recent strategies and developments: Sanofi S.A.
FIG 9 Recent strategies and developments: Zealand Pharma A/S
FIG 10 Recent strategies and developments: Arkray, Inc.